Praktyczne aspekty terapii reumatoidalnego zapalenia stawów przy użyciu metotreksatu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2024
Słowa kluczowe:
metotreksat, reumatoidalne zapalenie stawów, skuteczność, bezpieczeństwo
##plugins.themes.bootstrap3.article.main##
Abstrakt
Metotreksat jest antagonistą kwasu foliowego odgrywającym kluczową rolę w leczeniu wczesnego i zaawansowanego reumatoidalnego zapalenia stawów. Metotreksat odznacza się wysoką skutecznością kliniczną, hamowaniem uszkodzeń strukturalnych, dobrym profilem bezpieczeństwa, możliwością podawania doustnego lub podskórnego oraz niezrównaną efektywnością kosztową. Metotreksat może być stosowany zarówno w monoterapii, jak i jako wiodący lek w połączeniach z innymi syntetycznymi lub biologicznymi lekami modyfikującymi przebieg choroby.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rupiński, R. (2024). Praktyczne aspekty terapii reumatoidalnego zapalenia stawów przy użyciu metotreksatu . Medycyna Faktów , 17(2(63), 254-259. https://doi.org/10.24292/01.MF.0224.12
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985; 312: 818-22.
2. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion in the broad international panel of the rheumatologists in the 3D initiative. Ann Rheum Dis. 2009; 68: 1086-93.
3. Fiehn C. Methotrexat in der Rheumatologie. Z Rheumatol 2009; 68: 747-57.
4. Krijbolder DI, Verstappen M, van Dijk BT et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 2022; 400(10348): 283-94.
5. Combe B, Landewe R, Daien CI et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017; 76(6): 948-59.
6. Smolen JS, Landewé RBM, Bergstra SA et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023; 82: 3-18.
7. Fraenkel L, Bathon JM, England BR et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021; 73: 1108-23.
8. Kisiel B. Mechanizm działania metotreksatu. In: Tłustochowicz W. (red.) Metotreksat – zastosowanie w reumatologii i dermatologii. Termedia Wydawnictwa Medyczne, Poznań 2012: 9-12.
9. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002; 4: 266-73.
10. Riksen NP, Barrera P, van den Broek et al. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis. 2006; 65: 465-70.
11. Constantin A, Loubet-Lescoulié P, Lambert N et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum. 1998; 41: 48-57.
12. Shea B, Swinden MV, Tanjong Ghogomu E et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013; 2013: Cd000951.
13. Hoekstra M, Haagsma C, Neef C et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004; 31: 645-8.
14. Artacho A, Isaac S, Nayak R et al. The pretreatment gut micro-biome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis. Arthritis Rheumatol. 2021; 73: 931-42.
15. Stamp LK, Barclay ML, O’Donnell JL et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011; 38: 2540-7.
16. Braun J, Kästner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
17. Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014; 43: 470-6.
18. Müller-Ladner U, Rockwitz K, Brandt-Jurgens J et al. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J. 2010; 4: 15-22.
19. Tanaka Y. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2023; 33(4): 633-9.
20. Sugiyama D, Nishimura K, Tamaki K et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010; 69: 70-81.
21. Nayebirad S, Javinani A, Javadi M et al. The effect of smoking on response to methotrexate in rheumatoid arthritis patients: A systematic review and meta-analysis. Mod Rheumatol. 2023; 34(1): 68-8.
22. Stamp LK, O’Donnell JL, Chapman PT et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum. 2009; 60: 2248-56.
23. Heluany CS, Scharf P, Schneider AH et al. Toxic mechanisms of cigarette smoke and heat-not-burn tobacco vapor inhalation on rheumatoid-arthritis. Sci Total Environ. 2022; 809: 151097.
24. Negi S, Tandel N, Garg NK et al. Co-Delivery of Aceclofenac and Methotrexate Nanoparticles Presents an Effective Treatment for Rheumatoid Arthritis. Int J Nanomedicine. 2024; 19: 2149-77.
25. Negi S, Tandel N, Sharma P et al. Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation. Drug Discov Today. 2023; 28(8): 103671.
26. Kanagawa H, Masuyama R, Morita M et al. Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors. J Bone Min Metab. 2016; 34(5): 526-31.
27. Świerkot J, Gruszecka K, Matuszewska A et al. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp. 2015; 63: 397-404.
28. Nicolau J, Lequerre T, Bacquet H et al. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017; 84(4): 411-6.
29. Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta- analysis. PLoS ONE. 2020; 15(7): e0235637.
30. Judge A, Garriga C, Arden NK et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement. 2017; 3: 612-21.
2. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion in the broad international panel of the rheumatologists in the 3D initiative. Ann Rheum Dis. 2009; 68: 1086-93.
3. Fiehn C. Methotrexat in der Rheumatologie. Z Rheumatol 2009; 68: 747-57.
4. Krijbolder DI, Verstappen M, van Dijk BT et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 2022; 400(10348): 283-94.
5. Combe B, Landewe R, Daien CI et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017; 76(6): 948-59.
6. Smolen JS, Landewé RBM, Bergstra SA et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023; 82: 3-18.
7. Fraenkel L, Bathon JM, England BR et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021; 73: 1108-23.
8. Kisiel B. Mechanizm działania metotreksatu. In: Tłustochowicz W. (red.) Metotreksat – zastosowanie w reumatologii i dermatologii. Termedia Wydawnictwa Medyczne, Poznań 2012: 9-12.
9. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002; 4: 266-73.
10. Riksen NP, Barrera P, van den Broek et al. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis. 2006; 65: 465-70.
11. Constantin A, Loubet-Lescoulié P, Lambert N et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum. 1998; 41: 48-57.
12. Shea B, Swinden MV, Tanjong Ghogomu E et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013; 2013: Cd000951.
13. Hoekstra M, Haagsma C, Neef C et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004; 31: 645-8.
14. Artacho A, Isaac S, Nayak R et al. The pretreatment gut micro-biome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis. Arthritis Rheumatol. 2021; 73: 931-42.
15. Stamp LK, Barclay ML, O’Donnell JL et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011; 38: 2540-7.
16. Braun J, Kästner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
17. Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014; 43: 470-6.
18. Müller-Ladner U, Rockwitz K, Brandt-Jurgens J et al. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J. 2010; 4: 15-22.
19. Tanaka Y. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2023; 33(4): 633-9.
20. Sugiyama D, Nishimura K, Tamaki K et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010; 69: 70-81.
21. Nayebirad S, Javinani A, Javadi M et al. The effect of smoking on response to methotrexate in rheumatoid arthritis patients: A systematic review and meta-analysis. Mod Rheumatol. 2023; 34(1): 68-8.
22. Stamp LK, O’Donnell JL, Chapman PT et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum. 2009; 60: 2248-56.
23. Heluany CS, Scharf P, Schneider AH et al. Toxic mechanisms of cigarette smoke and heat-not-burn tobacco vapor inhalation on rheumatoid-arthritis. Sci Total Environ. 2022; 809: 151097.
24. Negi S, Tandel N, Garg NK et al. Co-Delivery of Aceclofenac and Methotrexate Nanoparticles Presents an Effective Treatment for Rheumatoid Arthritis. Int J Nanomedicine. 2024; 19: 2149-77.
25. Negi S, Tandel N, Sharma P et al. Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation. Drug Discov Today. 2023; 28(8): 103671.
26. Kanagawa H, Masuyama R, Morita M et al. Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors. J Bone Min Metab. 2016; 34(5): 526-31.
27. Świerkot J, Gruszecka K, Matuszewska A et al. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp. 2015; 63: 397-404.
28. Nicolau J, Lequerre T, Bacquet H et al. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017; 84(4): 411-6.
29. Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta- analysis. PLoS ONE. 2020; 15(7): e0235637.
30. Judge A, Garriga C, Arden NK et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement. 2017; 3: 612-21.